The VWF Gene von Willebrand Disease Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the VWF gene, which is responsible for von Willebrand Disease (VWD) - a genetic disorder that affects blood clotting. This test is crucial for individuals suspected of having VWD, as it can confirm the diagnosis and help in understanding the specific type and severity of the condition. Priced at 4400 AED, the test involves collecting a DNA sample, usually through a blood draw, and analyzing the genetic material for any abnormalities in the VWF gene. The results from this test can provide essential information for the management and treatment of von Willebrand Disease, aiding in the development of a personalized approach to care for affected individuals.
The GP1BA Gene von Willebrand Disease Platelet Type Genetic Test is a specialized diagnostic examination designed to detect mutations in the GP1BA gene, which are associated with von Willebrand Disease Platelet Type, also known as Platelet-type von Willebrand disease (PT-VWD). This condition is a rare bleeding disorder that affects the blood's ability to clot properly, leading to symptoms such as excessive bleeding from minor wounds, easy bruising, and prolonged bleeding after surgery or dental work. The test involves analyzing the patient's DNA to identify any genetic abnormalities in the GP1BA gene that could lead to this condition.
Conducted at DNA Labs UAE, a leading facility in genetic testing and diagnostics, this test provides critical information for the accurate diagnosis and management of PT-VWD. Understanding the genetic basis of the disease can help healthcare providers tailor treatment strategies to the individual's specific condition, potentially improving patient outcomes.
The cost of the GP1BA Gene von Willebrand Disease Platelet Type Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to detect the genetic markers associated with the condition. While the price may seem significant, the value of obtaining a precise diagnosis cannot be understated, as it opens the door to targeted treatments and informed healthcare decisions, ultimately enhancing the quality of life for individuals with PT-VWD.
The CSF3R gene plays a crucial role in the regulation of granulocyte production and function within the human body. Mutations in the CSF3R gene can lead to hereditary neutrophilia, a condition characterized by an abnormally high number of neutrophils, a type of white blood cell essential for combating infections. Identifying mutations in the CSF3R gene is crucial for diagnosing hereditary neutrophilia, understanding its pathogenesis, and guiding treatment options.
DNA Labs UAE offers a specialized genetic test to detect mutations in the CSF3R gene, aiding in the diagnosis of hereditary neutrophilia. This test is particularly valuable for individuals with a family history of neutrophilia or those exhibiting symptoms related to high neutrophil counts, such as recurrent infections or inflammation. The test cost is set at 4400 AED, reflecting the specialized nature of the analysis and the comprehensive insights it provides into the patient's genetic makeup concerning the CSF3R gene. By opting for this test at DNA Labs UAE, patients and healthcare providers can make informed decisions regarding the management of hereditary neutrophilia and related conditions.
The PEAR1 Gene Platelet Aggregation Disorder Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the PEAR1 gene, which can lead to platelet aggregation disorders. Platelets play a crucial role in blood clotting, and any irregularities in their function can result in excessive bleeding or clotting issues. The PEAR1 gene has been implicated in the regulation of platelet aggregation, making it a critical target for genetic testing in individuals experiencing symptoms of platelet dysfunction or those with a family history of bleeding disorders.
This test, priced at 4400 AED, involves collecting a DNA sample, usually through a blood draw, which is then analyzed in the laboratory to detect any genetic variations in the PEAR1 gene that might affect platelet function. The results from this test can provide valuable information for the diagnosis, management, and treatment of platelet aggregation disorders. It is particularly useful for guiding clinical decisions, including medication choices, and for assessing the risk of bleeding in surgical settings.
DNA Labs UAE offers this genetic test with the aim of enhancing patient care through personalized medicine. By identifying specific genetic causes of platelet aggregation disorders, healthcare providers can tailor treatment plans to the individual needs of their patients, potentially improving outcomes and reducing the risk of complications associated with these conditions.
The "FLI1 Gene Platelet Dense Granule Secretion Defect Excessive Bleeding Genetic Test" is a specialized diagnostic tool offered by DNA Labs UAE, designed to identify mutations in the FLI1 gene that are associated with platelet dense granule secretion defects. This condition can lead to excessive bleeding due to the impaired function of platelets, which are crucial for blood clotting. The test is crucial for individuals experiencing unexplained bleeding symptoms or those with a family history of bleeding disorders, as it can provide definitive genetic evidence of the condition.
Administered at a cost of 4400 AED, the test involves collecting a DNA sample, typically through a blood draw, which is then analyzed in the laboratory to detect any genetic abnormalities in the FLI1 gene. The results from this test can help healthcare providers make informed decisions regarding the management and treatment of the condition, potentially preventing severe bleeding episodes and improving the quality of life for affected individuals.
The RUNX1 Gene Platelet Disorder with Associated Myeloid Malignancy Genetic Test is a specialized diagnostic assessment offered by DNA Labs UAE. Priced at 4400 AED, this test is designed to identify mutations in the RUNX1 gene, which plays a crucial role in the normal development of blood cells. Mutations in the RUNX1 gene can lead to platelet disorders characterized by abnormal bleeding or bruising, and they are also associated with an increased risk of developing myeloid malignancies, such as leukemia. By detecting these genetic alterations, the test can provide essential information for the diagnosis, management, and treatment planning for individuals with or at risk of these conditions. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test is a critical tool for patients and healthcare providers in the management of platelet disorders and associated myeloid malignancies.
The CD36 Gene Platelet Glycoprotein IV Deficiency Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the CD36 gene. This gene is crucial for the proper functioning of platelet glycoprotein IV, a protein that plays a significant role in platelet aggregation, inflammation, and the metabolism of lipids. Deficiencies or abnormalities in this protein can lead to a range of health issues, including a predisposition to cardiovascular diseases and metabolic disorders.
The test is particularly relevant for individuals who have a family history of related health conditions or those experiencing symptoms that could be attributed to CD36 gene mutations. By analyzing the patient's DNA, the test can confirm the presence of specific mutations in the CD36 gene, providing valuable information for diagnosis, treatment planning, and genetic counseling.
Conducted at the state-of-the-art facilities of DNA Labs UAE, the test ensures accuracy and confidentiality. The cost of the CD36 Gene Platelet Glycoprotein IV Deficiency Genetic Test is 4400 AED, reflecting the comprehensive analysis and detailed reporting provided. Results from this test can guide healthcare professionals in developing personalized treatment strategies and advising on lifestyle adjustments to mitigate potential health risks associated with CD36 gene mutations.
The ALAS2 gene, associated with X-Linked Protoporphyria (XLP), plays a crucial role in the body's heme production process. Mutations in this gene can lead to protoporphyria erythropoietic, a condition characterized by a deficiency in heme, the oxygen-carrying component of red blood cells. This deficiency can cause a range of symptoms, including photosensitivity, causing painful reactions to sunlight, and, in severe cases, liver damage.
To diagnose this condition, a specific genetic test targeting the ALAS2 gene can be conducted. This test is essential for confirming the presence of mutations in the ALAS2 gene that are responsible for X-Linked Protoporphyria. It is a critical step in the diagnostic process, helping healthcare providers to develop a suitable management and treatment plan for affected individuals.
In the United Arab Emirates, DNA Labs UAE offers this specialized genetic test. The test cost is set at 4400 AED, reflecting the comprehensive analysis and detailed insights it provides into the patient's genetic makeup. By identifying mutations in the ALAS2 gene, the test plays a pivotal role in the diagnosis and understanding of X-Linked Protoporphyria, paving the way for targeted interventions and improved patient outcomes.
The "GGCX Gene Pseudoxanthoma Elasticum-Like Disorder with Multiple Coagulation Factor Deficiency Genetic Test" is a specialized diagnostic tool available at DNA Labs UAE, designed to identify mutations in the GGCX gene. This gene is crucial for the activation of certain proteins involved in blood coagulation and the health of connective tissues. Mutations in the GGCX gene can lead to a rare condition that exhibits characteristics similar to pseudoxanthoma elasticum, including abnormal mineralization of elastic fibers in tissues and a deficiency in multiple blood coagulation factors, leading to increased bleeding risk.
The test, which costs 4400 AED, involves collecting a DNA sample from the patient, usually through a blood draw or a cheek swab. The sample is then analyzed in the laboratory to detect any genetic abnormalities in the GGCX gene that may indicate the presence of this disorder. This genetic test is critical for early diagnosis and management of the condition, allowing for appropriate treatment plans to be devised to manage symptoms and prevent complications associated with coagulation deficiencies and connective tissue disorders.
Schimke Immunoosseous Dysplasia (SIOD) is a rare, autosomal recessive disorder characterized by spondyloepiphyseal dysplasia, renal disease, and T-cell immunodeficiency. The condition is attributed to mutations in the SMARCAL1 gene, which plays a crucial role in DNA repair and maintenance of genomic stability. Early diagnosis of SIOD is essential for managing symptoms and improving the quality of life for affected individuals.
The SMARCAL1 Gene Schimke Immunoosseous Dysplasia Genetic Test is a specialized diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the SMARCAL1 gene that are associated with the condition. This test is critical for confirming a clinical diagnosis of SIOD, enabling genetic counseling, and facilitating family planning decisions.
The test involves collecting a DNA sample, typically through a blood draw or cheek swab, which is then analyzed in the laboratory to identify any genetic alterations in the SMARCAL1 gene. DNA Labs UAE employs advanced genetic sequencing technologies to ensure accurate and reliable results.
The cost of the SMARCAL1 Gene Schimke Immunoosseous Dysplasia Genetic Test at DNA Labs UAE is 4400 AED. This price includes the cost of the sample collection, genetic analysis, and a comprehensive report detailing the findings. Patients and healthcare providers are encouraged to discuss the implications of the test results and explore appropriate management strategies for SIOD.
By offering this genetic test, DNA Labs UAE provides a vital resource for individuals and families affected by Schimke Immunoosseous Dysplasia, contributing to better disease understanding, management, and research into potential treatments.
